

Congress of the United States
House of Representatives
Washington, DC 20515

September 9, 2025

Secretary Robert F. Kennedy, Junior
Department of Health and Human Services
200 Independence Avenue SW
Washington, DC 20201

Dear Secretary Kennedy,

We, the undersigned members of Congress, write to express our concerns regarding the recently announced 340B Rebate Model Pilot Program. As the Department of Health and Human Services (HHS) notes, this change would “fundamentally shift how the 340B Program has operated for over 30 years.” Congress intended the 340B Program to enable the nation’s safety-net providers to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. An unchecked rebate model would severely undermine that purpose. We urge you to abandon the Rebate Model Pilot Program, or if the program must move forward, to proceed with the utmost caution and impose stronger guardrails to ensure the 340B program is not entirely dismantled.

As HHS is aware, last year, several multinational drug manufacturers—Bristol Myers Squibb (BMS), Eli Lilly, Johnson & Johnson (J&J), Novartis, and Sanofi—attempted to unilaterally impose rebate models on certain covered entities and drugs, despite a clear lack of statutory authority. We are grateful to the Health Resources & Services Administration (HRSA) for its swift and consistent enforcement efforts blocking manufacturers’ unlawful attempts to restructure the program without Secretarial approval. HRSA’s interpretation and enforcement against the rebate models were upheld by the U.S. District Court in the District of Columbia.¹

We are concerned that HHS’s pilot program will severely damage community health centers, safety net hospitals, and other providers that rely on the 340B program to provide comprehensive, quality services to their patients and communities.

The rebate model pilot program will require all covered entities to purchase drugs on the CMS Medicare Drug Price Negotiation Selected Drug List at the wholesale acquisition cost – the highest sticker price that manufacturers offer, which is rarely actually paid by purchasers in the health care system. This will require 340B providers to float significant amounts of cash to drug

¹ “Eli Lilly and Company et al v. Robert F. Kennedy et al.” (2025)
https://sponsors.aha.org/rs/710-ZLL-651/images/2025-05-15_340B_Rebate_Models_Ruling

companies in hopes of a rebate being paid. Further, these drugs, despite their prices being reduced through price negotiation, are still some of the costliest drugs in the Medicare Part D program. If the entire 340B program moved to a rebate model, the average Disproportionate Share Hospital in the country would be forced to float an estimated \$72.2 million to manufacturers annually.²

This is a cost most 340B providers, many of whom are experiencing financial instability, simply cannot afford. 340B hospitals already have substantially lower—negative on average—operating margins compared to non-340B hospitals. And in 2023, nationally, nearly half of health centers had negative operating margins; overall net margins were 1.6 percent.³ These changes threaten 340B providers' ability to provide care and to keep their doors open to serve low-income communities.

In addition, we are concerned that this rebate model will be used by manufacturers as a backdoor to recoup their own profits that may have been lost as a result of lowering prices through the Medicare Drug Price Negotiation Program (MDPNP). This was never Congress's intent in establishing the MDPNP. While we appreciate HRSA's attempts to place guardrails around this pilot program, these guardrails will not be sufficient to prevent aggressive tactics by manufacturers to deny claims and siphon money away from providers and their patients.

Finally, as we have affirmed on multiple occasions, we continue to believe that the rebate approach contravenes Congressional intent in establishing the 340B program and over three decades of precedent set by HRSA that distinguishes rebates and retroactive discounts from upfront 340B discounts.⁴

As such, we urge you to cancel the pilot program. However, if HHS chooses to continue with this pilot, we request answers to the following questions, no later than September 15, 2025:

1. HHS notes that this pilot would “fundamentally shift how the 340B Program has operated for over 30 years.” Yet the timeline for implementation of this pilot leaves little room for meaningful covered entity input, while mandating significant additional costs for those entities.

² Manufacturer 340B Rebate Models Threaten Safety-Net and Rural Hospitals and Would Harm Patients, 340B Health (2025).

https://www.340bhealth.org/files/340B_Health_MANUFACTURER_340B_REBATE_MODELS_Report.pdf

³ Federman, Sara; Bryan, Alexandra; Horstman, Celia; Lewis, Corinne. Community Health Centers Are Serving More Patients Than Ever, but Financial Challenges Loom Large, The Commonwealth Fund (2024).

<https://www.commonwealthfund.org/blog/2024/community-health-centers-are-serving-more-patients-ever-financial-challenges-loom-large>

⁴ Final Notice on Entity Guidelines, 59 Fed. Reg. 25112; Notice on Initial Guidance, 58 Fed. Reg. 27291, 27292.

- a. What legal authority does HHS cite to support a 30-day public comment period, after which HHS is “under no obligation to respond or act on” any comments, in making this significant change?
 - b. What is HHS’s justification for imposing such significant changes on a rushed timeline, including only 30 days for public comment, one week to review public comments including input from 340B providers who have otherwise been uninvolved in the process, and four weeks to review manufacturers’ proposed plans?
2. How will the Information Technology (IT) platform be selected to ensure reduced administrative and logistic burden for covered entities, while avoiding any conflicts of interest? Will manufacturers be required to consider input from covered entities?
3. With regards to the determination of claims’ validity and issuance of rebates under the program:
 - a. What are HHS’s plans for ongoing audits and oversight to determine whether manufacturers are appropriately approving claims and issuing rebates in a timely manner?
 - b. If manufacturers do not pay rebates within 10 days of receiving covered entities’ submissions of data as required by the rebate model parameters, inappropriately deny entities’ claims, or otherwise use this pilot program to abuse the 340B Program, what enforcement tools will HHS use against noncompliant manufacturers? Will there be any special expedited procedures to allow covered entities to use the administrative dispute resolution (ADR) process to contest invalid manufacturer actions?
 - c. What additional criteria do HHS envision as permissible and impermissible for manufacturers to use as grounds to deny claims? For example, will HHS permit manufacturers to deny rebates by alleging that providers are not complying with the manufacturer’s unilaterally imposed restrictions on contract pharmacy?
4. The guidance states that “no additional administrative costs of running the rebate model shall be passed onto the covered entities.” How will HHS ensure this includes all administrative costs related to this rebate model pilot program, including labor costs and the costs of contesting denials? What enforcement mechanism will ensure that manufacturers pay all such costs in a timely manner?
5. The announcement notes that manufacturers can apply to participate for a “minimum of 1 year.”
 - a. What is the maximum amount of time HHS will permit manufacturers to run these rebate models?
 - b. Does HHS plan to re-evaluate the rebate model after one year to assess whether it will continue to permit manufacturers to remain in these rebate arrangements?
6. HHS states that it will evaluate “data and reports received from the participating manufacturers on the effectiveness of the model and covered entity and other stakeholder

feedback,” after which HHS may consider expanding the rebate model to other drugs purchased under the 340B program.

- a. Which performance measures will the agency use to measure effectiveness?
 - b. How will the ability of covered entities to provide care to underserved patients, as well as other feedback from covered entities, be weighed in the assessment of effectiveness?
 - c. Will the agency commit to make public the results of the assessments it conducts of the model’s effectiveness?
 - d. On what basis would the agency decide to increase the number of drugs subject to rebates by adding drugs with negotiated prices coming into effect in 2027 under the MDPNP?
 - e. On what basis would the agency determine to include drugs that are not under the MDPNP?
7. For many years and across several administrations, HHS has requested increased resources for implementation and oversight over the 340B Program. Yet this pilot program would significantly increase administrative burden for HHS staff, whose new responsibilities will include reviewing manufacturers’ applications and resolving any issues within 30 days from receipt, performing audits and ADR for any deviations from program guidelines, addressing issues raised by covered entities if there are issues with rebate delays and denials, and fielding any other administrative or logistical issues emerging through implementation of the rebate model. What is HHS’s plan to implement such a pilot program while maintaining regular oversight of the 340B program?


Sincerely,



Doris Matsui
Member of Congress



Dusty Johnson
Member of Congress



Debbie Dingell
Member of Congress



Tracey Mann
Member of Congress



Marie Gluesenkamp Perez
Member of Congress




Mark Takano
Member of Congress



John Rose
Member of Congress



Joseph D. Morelle
Member of Congress



Nydia M. Velázquez
Member of Congress




Lloyd Doggett
Member of Congress



Paul Tonko
Member of Congress




Jim Tokuda
Member of Congress




Stephen F. Lynch
Member of Congress




Shontel M. Brown
Member of Congress




Nikki Budzinski
Member of Congress



William R. Keating
Member of Congress




Yvette D. Clarke
Member of Congress




Grace Meng
Member of Congress



Becca Balint
Member of Congress



Mark Pocan
Member of Congress




Sharice L. Davids
Member of Congress




Andre Carson
Member of Congress



Lori Trahan
Member of Congress




Angie Craig
Member of Congress



Jan Schakowsky
Member of Congress



Marc A. Veasey
Member of Congress




Nikema Williams
Member of Congress



Jim Costa
Member of Congress



Ayanna Pressley
Member of Congress



Gabe Vasquez
Member of Congress



Ilhan Omar
Member of Congress



Sean Casten
Member of Congress



Haley M. Stevens
Member of Congress




Dina Titus
Member of Congress



Mike Thompson
Member of Congress



Lateefah Simon
Member of Congress



Juan Vargas
Member of Congress



Betty McCollum
Member of Congress



John Garamendi
Member of Congress



Greg Casar
Member of Congress



J. Luis Correa
Member of Congress



Chellie Pingree
Member of Congress




Emilia Strong Sykes
Member of Congress



Sara Jacobs
Member of Congress



Ed Case
Member of Congress



Kelly Morrison
Member of Congress



Steve Cohen
Member of Congress



Henry C. "Hank" Johnson, Jr.
Member of Congress



Chrissy Houlahan
Member of Congress



Chris Pappas
Member of Congress



Delia C. Ramirez
Member of Congress



Adam Smith
Member of Congress



David G. Valadao
Member of Congress



Sam Graves
Member of Congress



Dwight Evans
Member of Congress




Rick Larsen
Member of Congress



Julia Brownley
Member of Congress



Val Hoyle
Member of Congress



Jared Golden
Member of Congress



Greg Landsman
Member of Congress



Raja Krishnamoorthi
Member of Congress



Valerie P. Foushee
Member of Congress




Zoe Lofgren
Member of Congress



Salud Carbajal
Member of Congress



Rashida Tlaib
Member of Congress




Andrea Salinas
Member of Congress



Veronica Escobar
Member of Congress



Ritchie Torres
Member of Congress




Bennie G. Thompson
Member of Congress



Emanuel Cleaver, II
Member of Congress




Greg Stanton
Member of Congress



Jack Bergman
Member of Congress




Thomas R. Suozzi
Member of Congress



Adriano Espaillat
Member of Congress



Ro Khanna
Member of Congress



Seth Magaziner
Member of Congress




Kim Schrier, M.D.
Member of Congress



Maxine Dexter
Member of Congress



George Latimer
Member of Congress



Sylvia R. Garcia
Member of Congress




Derek T. Tran
Member of Congress



Eleanor Holmes Norton
Member of Congress




James P. McGovern
Member of Congress



Jesús G. "Chuy" García
Member of Congress



Don Bacon
Member of Congress




Kathy Castor
Member of Congress



Young Kim
Member of Congress



Alexandria Ocasio-Cortez
Member of Congress




Hillary J. Scholten
Member of Congress



Patrick K. Ryan
Member of Congress



Eric Swalwell
Member of Congress



Mike Flood
Member of Congress



Mike Quigley
Member of Congress




Dan Goldman
Member of Congress



Lois Frankel
Member of Congress



Maggie Goodlander
Member of Congress




Gilbert Ray Cisneros, Jr.
Member of Congress




Debbie Wasserman Schultz
Member of Congress



Lizzie Fletcher
Member of Congress



Jerrold Nadler
Member of Congress



Suzanne Bonamici
Member of Congress




Lucy McBath
Member of Congress




Mary Gay Scanlon
Member of Congress



Shri Thanedar
Member of Congress




Timothy M. Kennedy
Member of Congress



Suzan K. DelBene
Member of Congress




Pete Stauber
Member of Congress



Judy Chu
Member of Congress



Emily Randall
Member of Congress




Rob Bresnahan, Jr.
Member of Congress




Kimberlyn King-Hinds
Member of Congress



Gwen S. Moore
Member of Congress




Danny K. Davis
Member of Congress



Gregory W. Meeks
Member of Congress



Michael V. Lawler
Member of Congress



Jonathan L. Jackson
Member of Congress




Robert Garcia
Member of Congress



Ami Bera, M.D.
Member of Congress




Josh Harder
Member of Congress



Sanford D. Bishop, Jr.
Member of Congress



Terri A. Sewell
Member of Congress



Shomari Figures
Member of Congress



John W. Mannion
Member of Congress



Eric Sorensen
Member of Congress



Darren Soto
Member of Congress




Jasmine Crockett
Member of Congress




Frank J. Mrvan
Member of Congress



Ted W. Lieu
Member of Congress



Henry Cuellar
Member of Congress



Kristen McDonald Rivet
Member of Congress



Jimmy Panetta
Member of Congress



Frederica S. Wilson
Member of Congress



Troy A. Carter, Sr.
Member of Congress



Joyce Beatty
Member of Congress (OH-03)



Jefferson Van Drew
Member of Congress



Diana DeGette
Member of Congress



Jason Crow
Member of Congress



Robin L. Kelly
Member of Congress




Mark DeSaulnier
Member of Congress



Maxine Waters
Member of Congress



Josh Riley
Member of Congress



Kweisi Mfume
Member of Congress



Julie Johnson
Member of Congress



Seth Moulton
Member of Congress




Derek Schmidt
Member of Congress



Joaquin Castro
Member of Congress



Bill Foster
Member of Congress




Sam T. Liccardo
Member of Congress



Nick LaLota
Member of Congress




Nancy Pelosi
Member of Congress



Michael K. Simpson
Member of Congress



Derrick Van Orden
Member of Congress




Cleo Fields
Member of Congress



Chris Deluzio
Member of Congress



Pablo José Hernández
Member of Congress



Joe Neguse
Member of Congress



Gabe Amo
Member of Congress



Bradley Scott Schneider
Member of Congress



Susie Lee
Member of Congress



Madeleine Dean
Member of Congress



Pramila Jayapal
Member of Congress




Mike Bost
Member of Congress



Dan Meuser
Member of Congress



Randy Feenstra
Member of Congress



Adam Gray
Member of Congress



Andrew R. Garbarino
Member of Congress